Medical Cannabis Prescription Assessment Online

Prescription-assessment information.

This page explains how a clinical assessment can lead to a prescribing decision. Paying for or attending a consultation does not guarantee prescribing, regulatory access, pharmacy stock or a particular medicine.

Searching for a ‘medical cannabis prescription online’ can make the process sound transactional. People who instead search ‘medical marijuana’, ‘medical weed’ or ‘MMJ’ can use DocTel’s medical-marijuana terminology guide to translate those terms into the Australian clinical context. In legitimate clinical care, the prescription is the possible outcome of an assessment, not the product being sold. The doctor first needs enough information to decide whether medicinal cannabis is appropriate, whether another treatment should be considered and whether telehealth is a suitable setting for the assessment.

DocTel’s Medicanna pathway is consultation-first. A prescription is not guaranteed and the practitioner is not required to prescribe a requested product. The consultation may result in prescribing, a request for further information, a different treatment recommendation or advice to obtain face-to-face care.

This page focuses specifically on the prescription assessment journey. For broader information about medicinal-cannabis regulation, see the Australian regulatory guide. For service information, visit Cannabis Telehealth Australia.

A focused consultation is easier when the patient can describe the main problem clearly, but the assessment itself is broader than a single symptom question. Depending on the individual case, a practitioner may consider some or all of the following before reaching a prescribing decision:

• The presenting problem and its duration — what the main issue is, how long it has been present, and how it affects sleep, function or daily life.
• Diagnosis, where known — an existing diagnosis, or the working impression if a formal diagnosis has not yet been made.
• Previous treatment and response — what has already been tried, whether it helped, and why it was stopped or continued.
• Current medicines and other substances — prescription medicines, over-the-counter products, supplements and alcohol use relevant to safety.
• Relevant medical history — conditions that could affect suitability, dosing or monitoring.
• Mental-health history, where clinically relevant — not to disqualify a patient by default, but because it can materially change the risk assessment.
• Contraindications and risk factors — including pregnancy, significant interactions, or a need for urgent or face-to-face care instead.
• The patient’s treatment goals — what outcome would count as a reasonable result, so that success or failure can later be judged against something specific.
• Whether telehealth is an adequate setting — or whether a physical examination, further investigation or specialist input is needed first.

This is not a rigid checklist every practitioner works through identically, and not every item applies to every patient. It illustrates the kind of clinical reasoning behind the decision, rather than a form to be completed. Patients can make the process more efficient by bringing an accurate medication list and a clear, honest account of what has already been tried.

A patient may be unsuitable for medicinal cannabis even when they have persistent symptoms. Examples can include a clinical picture that has not been adequately assessed, a need for urgent care, significant contraindications, medication interactions, pregnancy, a concerning mental-health history, or a situation where another treatment should be prioritised.

The clinician also weighs whether the expected benefit is sufficient to justify the risks and uncertainties involved, and may need to consider whether a physical examination or face-to-face review is necessary before making a treatment decision. None of this reflects a quota or a reluctance to prescribe — it reflects the same standard of clinical reasoning expected in any area of medicine.

When the practitioner decides medicinal cannabis is appropriate, the prescription should reflect an individual treatment plan rather than a generic product request. The formulation, route, dose and instructions depend on the clinical assessment and the lawful product/access pathway.

Most medicinal-cannabis products in Australia are unapproved therapeutic goods and may be accessed through TGA pathways such as the Special Access Scheme or Authorised Prescriber pathway. The regulatory step and the clinical prescription are connected, but they are not the same thing.

The patient should understand how to use the prescribed medicine, what treatment goal is being monitored, what adverse effects matter and when review is required. For deeper guidance on storage, impairment, adverse effects and monitoring responsibilities, see DocTel’s medicinal-cannabis safety and standards guide.

A clinically responsible service must allow the practitioner to decline prescribing, ask for additional records or recommend another care pathway. Payment is for the assessment, not a guaranteed medicine — the same principle that applies to any other specialist medical consultation where a particular outcome cannot be promised in advance. A consultation that ends without a prescription has still done its job if it has correctly identified that treatment is not appropriate right now.

After a prescription is issued, supply occurs through a pharmacy pathway. Product availability can vary, and a prescription does not guarantee that a particular pharmacy will have a particular product in stock.

Patients should not independently replace the prescribed medicine with another product or formulation. If the pharmacy cannot supply the item as prescribed, the pharmacist or prescriber may need to clarify the appropriate next step.

DocTel’s medicinal-cannabis pathway is not an online shop. The clinical service and pharmacy dispensing are separate parts of care.

• Use the prescription and pharmacy process explained by the practitioner.
• Ask before substituting products or changing route of administration.
• Keep the pharmacy label and product instructions.
• Contact the clinical service if the prescribed plan cannot be followed or if significant adverse effects occur.

A prescription should not become an indefinite treatment without reassessment. Follow-up allows the clinician to determine whether symptoms or function have improved, whether adverse effects are acceptable and whether the treatment plan should continue, change or stop.

Patients may be asked about dose, timing, adherence, side effects, sleep, mood, function and changes in other medicines. A useful review focuses on meaningful outcomes rather than only whether the patient wants another prescription. For the safety-monitoring detail behind adverse effects and what should prompt an earlier review, see DocTel’s safety and standards guide.

If the clinical situation has changed substantially, the practitioner may require a longer review, updated records or face-to-face assessment.

Search terms such as ‘instant cannabis prescription’, ‘same-day cannabis prescription’ or ‘online weed prescription’ can imply that speed is the main feature of the service. Same-day appointments may sometimes be available, but the clinical decision still needs to be made properly.

A responsible service should not guarantee approval, advertise a particular medicine as the inevitable outcome, or reduce a medical assessment to a payment step. Patients should expect questions, risk assessment and the possibility that prescribing is declined.

DocTel’s eligibility check can help identify obvious reasons the Medicanna pathway may not be suitable before a patient books, but the final decision belongs to the treating practitioner.

Telehealth is not appropriate for every presentation. Urgent or rapidly worsening symptoms, severe shortness of breath, chest pain, acute confusion, suicidal thoughts, new neurological deficits, severe injury or another emergency concern require urgent assessment rather than an online medicinal-cannabis consultation.

A practitioner may also recommend face-to-face assessment when diagnosis is uncertain, a physical examination is important, relevant records are unavailable or the clinical risk is too high for telehealth alone.

That is not a failed consultation. It is an appropriate clinical boundary.

A repeat prescription request can feel routine to a patient who has already used medicinal cannabis, but the prescriber still has to consider whether ongoing treatment remains appropriate. The relevant review may be brief or more detailed depending on the clinical situation, the time since the last consultation, treatment response and any new risks.

Patients should be prepared to explain how the medicine has been used, whether the intended outcome improved, what adverse effects occurred and whether other medicines or health conditions have changed. A practitioner may decline or defer a repeat when follow-up information is inadequate or when the clinical picture has materially changed.

Repeat prescribing should therefore be understood as continuation of a treatment relationship, not as an automatic refill transaction.

Patients sometimes arrive with a specific product in mind, often based on a friend’s experience or something read online. A practitioner may reasonably decline that specific request, or decline to prescribe at all, for several distinct reasons — and understanding them helps set realistic expectations before the consultation:

• Insufficient information — the practitioner cannot yet form a safe, reasoned opinion from what has been provided.
• Another treatment may be more appropriate — including an existing, better-evidenced option that has not yet been tried.
• A safety concern or contraindication — a factor in the patient’s history, current medicines or circumstances that makes the specific product or medicinal cannabis generally unsuitable right now.
• A need for physical examination or investigations — findings that cannot be obtained through a telehealth consultation alone.
• A need for another practitioner or specialist — where the presenting problem sits outside what a single consultation can safely resolve.
• An unclear clinical rationale — where the connection between the patient’s problem and the specific requested product has not been established.

None of these reasons reflect a flaw in the patient or a failure of the consultation. They reflect ordinary clinical decision-making, applied to a treatment category that happens to attract more product-specific requests than most other prescription medicines.

A useful assessment leaves both patient and practitioner with a clear treatment rationale. The patient should know why the medicine is being considered, what outcome would count as success, which risks are most relevant and when review should occur.

The practitioner, in turn, should have enough information to document the decision and to recognise when treatment is not working. This is particularly important with therapies where products and cannabinoid profiles can vary and where dose changes may alter impairment or tolerability.

A prescription consultation should finish with practical clarity. Patients can ask what outcome the doctor expects to monitor, when the next review should occur, which adverse effects require earlier contact and what to do if the pharmacy cannot supply the prescribed medicine. It is also reasonable to ask whether driving, work duties or other medicines create additional precautions. Clear answers make the treatment plan safer and reduce the chance that the patient has to improvise after the appointment.

If you are considering medicinal cannabis, DocTel Medicanna provides a telehealth assessment pathway. The consultation is a clinical assessment and does not guarantee a prescription or a particular medicine.